Breast cancer treatments now often include Vitamin D

Exploring factors that influence vitamin D deficiency continuum across breast cancer patients' care: insights from a tertiary health population

BMC Cancer Nov 2026 https://doi.org/10.1186/s12885-026-17325-z

John O. Ogunbileje • Victor Adekanmbi • Rohit Gulati

Vitamin D deficiency has prognostic implications in breast cancer care. Identifying patients at high risk for vitamin D deficiency across the breast cancer care continuum can improve testing and supplementation strate­gies. This study aimed to describe serum vitamin D distributions in patients receiving breast cancer care and to identify predictors of vitamin D deficiency.

Method A retrospective cross-sectional analysis of 14,773 patients with at least one serum 25-hydroxyvitamin D (25(OH)D) measurement was performed. Patients were categorized into three breast diagnostic groups based on their ICD-10 code: current breast cancer (C50), screening (Z12.39), and personal history (Z85.3). 25(OH)D levels were classified as deficient (<20 ng/mL), insufficient (20-29.9 ng/mL), and sufficient (>30 ng/mL), with severe deficiency defined as <10 ng/mL and <15 ng/mL. One-way ANOVA compared the mean of 25(OH)D levels across different breast diagnostic groups. Multivariable logistic regression examined predictors of low 25(OH)D levels (<10 ng/mL and <15 ng/mL), adjusting for age, breast diagnostic group, and ethnicity.

Result Of the 14,773 patients, 99.8% were female, with a mean age of 54.8 ± 12.9 years. The overall mean serum 25(OH)D concentration was 37.3 ± 19.5 ng/mL. Serum 25(OH)D levels were higher in patients with current breast cancer (42.1 ng/mL) and those with a personal history (42.5 ng/mL) than in screening attendees (35.7 ng/ mL). Significant differences among the groups were confirmed by ANOVA (F(2, 14,770) = 152.2, p < 0.0001). Overall, 14.4% were deficient (<20 ng/mL), with 6.8% severely deficient (<15 ng/mL). Severe deficiency was most common in Z12 (7.6%), followed by C50 (4.2%) and Z85 (3.4%). Increasing age was protective against deficiency, with each 10-year increase reducing the odds (aOR = 0.88 for <10 ng/mL; aOR = 0.84 for <15 ng/mL). Women with breast cancer had lower odds of deficiency than screening patients (C50: aOR 0.66; Z85: aOR 0.56). Hispanic women had higher odds of deficiency at <15 ng/mL (aOR 1.44) than non-Hispanic women.

Conclusion Vitamin D deficiency is prevalent among younger women, those undergoing breast cancer screen­ing, and Hispanic women. Targeted testing by age, diagnostic group, and ethnicity has the potential to optimize resource allocation for at-risk patients and improve supplementation strategies throughout the breast oncology care continuum.

PDF


Vitamin D helps after diagnosis

Vitamin D also prevents Cancers and many other health problems

Click on a tag to see studies: Cancer - Breast (264) Vitamin D (11,513)